Testing a New Drug in People With Liver Problems
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy clinical trials.
This study tests how the body processes and tolerates a new experimental drug (MDR-001) in people with mild to moderate liver disease. The research helps doctors understand if the drug is safe and how it works when liver function is reduced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Mild to moderate chronic liver disease (such as hepatitis B or C, or alcoholic liver disease) with stable condition and stable medications for at least 14 days
- Healthy kidney function (eGFR ≥60 mL/min/1.73m²)
- Normal heart rhythm on EKG and no family history of sudden heart problems
- Able to swallow and digest food normally without frequent nausea, vomiting, or active stomach ulcers
- Willing to use effective birth control and not donate blood for at least 6 months after the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new drug called MDR-001 works when taken with two common medications (rifampin and itraconazole). Researchers want to understand if these drugs affect each other in healthy volunteers, which helps ensure the new drug is safe before testing it in patients.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
Hear when a new Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.